Subtype
Prostate Adenocarcinoma
CI-CAN-00003766PRADExplore in graph →
133 active trials1 approved drugs3 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003766PRADExplore in graph →
Clinical trials
433 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (71)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04286386 | Development and Evaluation of a Quantitative HP MRI for Clinical Prostate Cancer Exam | withdrawn | — | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Sep 15, 2026 | clinicaltrials |
| NCT06982222 | Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 0 | Aug 28, 2026 | clinicaltrials |
| NCT06528210 | Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer | withdrawn | Phase 2 | 0 | OHSU Knight Cancer InstituteOTHER | 0 | Sep 23, 2025 | clinicaltrials |
| NCT03581500 | Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Predicting Treatment Response in Patients With Prostate Cancer | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 23, 2025 | clinicaltrials |
| NCT05156372 | Adjuvant High-intensity Interval Training During Chemotherapy in Metastatic Prostate Cancer Patients(HIIT PCa) | withdrawn | N/A | 0 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Feb 26, 2024 | clinicaltrials |
| NCT03494803 | Detection of Prostate Cancer With Non-invasive Method Based on DNA Methylation of Circulated Tumor DNA, PBMC | withdrawn | — | 0 | HKGepitherapeuticsINDUSTRY | 1 | Dec 22, 2023 | clinicaltrials |
| NCT04781374 | Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer | withdrawn | Phase 2 | 0 | Beth Israel Deaconess Medical CenterOTHER | 1 | Jul 11, 2023 | clinicaltrials |
| NCT03982173 | Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors(MATILDA) | withdrawn | Phase 2 | 0 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 0 | Jan 26, 2023 | clinicaltrials |
| NCT04331717 | Bariatric Arterial Embolization for Men Starting Hormones for Prostate Cancer(BASH-PC) | withdrawn | Phase 2 | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 2, 2022 | clinicaltrials |
| NCT04020094 | Perioperative Atezolizumab With MVA-BN-Brachyury and PROSTVAC For Intermediate-Risk And High-Risk Localized Prostate Cancer(AtezoVax) | withdrawn | Phase 2 | 0 | University of UtahOTHER | 1 | Sep 22, 2021 | clinicaltrials |
| NCT04399824 | Focal Radiation Therapy for the Treatment of Low or Intermediate-Risk Prostate Cancer | withdrawn | N/A | 0 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 6, 2020 | clinicaltrials |
| NCT01859689 | Internal Radiation Therapy in Treating Patients With Low-Risk Prostate Cancer | withdrawn | Phase 2 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 0 | Jul 27, 2020 | clinicaltrials |
| NCT02597894 | Targeted Biopsies in Determining Response in Patients With Prostate Cancer Undergoing High-Dose-Rate Brachytherapy | withdrawn | N/A | 0 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 24, 2020 | clinicaltrials |
| NCT03147196 | Bicalutamide and Raloxifene Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery | withdrawn | Phase 2 | 0 | Mayo ClinicOTHER | 0 | Jan 22, 2019 | clinicaltrials |
| NCT00598858 | Neoadjuvant Docetaxel on Newly Diagnosed Intermediate and High Grade Cancer of the Prostate(2007-5904) | withdrawn | Phase 2 | 0 | John P. FruehaufOTHER | 0 | Dec 8, 2016 | clinicaltrials |
| NCT01368003 | STA-9090 in Castration-Resistant Prostate Cancer With Assessment of Androgen Receptor Pathway Signaling | withdrawn | Phase 2 | 0 | Toni Choueiri, MDOTHER | 1 | Sep 1, 2015 | clinicaltrials |
| NCT01838265 | Trial of Prostate Cancer Patients Undergoing Active Surveillance With or Without MRI-Guided Management(MGM) | withdrawn | — | 0 | University of MiamiOTHER | 1 | Dec 8, 2014 | clinicaltrials |
| NCT00003517 | Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer | withdrawn | Phase 2 | 0 | Burzynski Research InstituteOTHER | 1 | Jul 10, 2013 | clinicaltrials |
Data updated 15 days agoSource updated Sep 15, 2026source: clinicaltrials